I-124 Evuzamitide PET/CT is More Sensitive than Tc-99m Pyrophosphate forthe Diagnosis of Hereditary Transthyretin Cardiac Amyloidosis

Sep 30, 2023 Posters & Publications

AUTHORS: Dia A. Smiley1, DO, Andrew J. Einstein1,2, MD, PhD, Denisse Santana Del Rosario1, MD, Nicholas Chan1, MD, Akiva Mintz2, MD, PhD, Kim Goldner2, CNMT,RT, Stephen T. Helmke1 RDCS, MPH, Margaret O. Cuomo1, NP, Ani Nalbandian1, MD, Sergio Teruya1, MD, Samantha...

I-124 Evuzamitide PET/CT is More Sensitive than Tc-99m Pyrophosphate for the Diagnosis of Hereditary Transthyretin Cardiac Amyloidosis

Sep 30, 2023 Posters & Publications

AUTHORS: Dia Smiley, Andrew Einstein, Denisse Santana, Nicholas Chan, Akiva Mintz, Kimberly Goldner, Stephen Helmke, Margaret Cuomo, Ani Nalbandian, Sergio Teruya, Samantha Guadalupe, Jeffeny De Los Santos, Alfonsina Mirabel, Mary Paulino, Kimberly Collado, Carlos...

Attralus Receives FDA and EMA Orphan Designation for AT-01 (Iodine (I-124) Evuzamitide), an Investigational Diagnostic for the Management of AL and ATTR Amyloidosis

Dec 19, 2022 Press Releases

PDF Version SAN FRANCISCO – December 19, 2022 – Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, announced today that the European Commission (EC) and European...

Attralus Announces New Clinical Data in ATTR CM and AL With AT-01 (Iodine (I-124) Evuzamitide), a Novel Amyloid-Specific Imaging Agent

Sep 12, 2022 Press Releases

PDF Version AT-01 shows increased LV uptake and LV amyloid activity in all cardiac ATTR and AL subjects, but in none of the controls (100% accuracy) AT-01 demonstrates significantly higher left ventricular uptake in ATTR-CMP participants than florbetapir SAN...

Attralus Announces Presentation of Clinical Data for AT-01 (Iodine (I-124) Evuzamitide), a Novel Amyloid-Specific Imaging Agent, at the 18th International Symposium on Amyloidosis

Sep 8, 2022 Press Releases

PDF Version AT-01 is a first-in-class pan-amyloid imaging agent capable of detecting diverse types of systemic amyloidosis in multiple organs Sensitivity in those with previously diagnosed cardiac disease was 100% in ATTR and 93% in AL Organ-specific changes in...